<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="770">
  <stage>Registered</stage>
  <submitdate>20/09/2005</submitdate>
  <approvaldate>26/09/2005</approvaldate>
  <actrnumber>ACTRN12605000514606</actrnumber>
  <trial_identification>
    <studytitle>EPISODE II: Prevention of relapse following early psychosis</studytitle>
    <scientifictitle>EPISODE II: Prevention of relapse following early psychosis using combined family and individual CBT</scientifictitle>
    <utrn />
    <trialacronym>Episode II</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Early psychosis</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study aims to evaluate via a randomized controlled trial a combined individual and family-based psychosocial intervention aimed at relapse prevention following remission from first-episode psychosis in young people aged 15-25 years compared with treatment as usual in a first episode psychosis service.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluation will include the rate of relapse for participants in the relapse-prevention intervention (of approximately 6-months duration), compared with treatment as usual within a specialized first-episode service</outcome>
      <timepoint>At 6 month intervals over a 2 year period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Evaluation will include the time to relapse for participants in the relapse-prevention intervention (of approximately 6-months duration), compared with treatment as usual within a specialized first-episode service</outcome>
      <timepoint>At 6 month intervals over a 2 year period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The impact upon awareness of illness, secondary morbidity, quality of life, medication adherence, substance abuse, and family burden will be evaluated using standardized interview schedules and questionnaires.</outcome>
      <timepoint>At 6-monthly intervals over a 2-year period following participation in the relapse-prevention intervention (of approximately 6-months duration), compared with treatment as usual within a specialized first-episode service.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1) Eligible for EPPIC services (DSM-IV diagnosis of a psychotic disorder or mood disorder with psychotic features, no more than 6 months of prior treatment with an antipsychotic prior to registration with EPPIC) and Barwon Heath First Episode Psychosis Service (see EPPIC criteria above), with a maximum of 12 months of treatment received within the service; (2) Able to converse in English without an interpreter; and (3) Have reached complete, or near-complete remission of positive psychotic sypmtoms for a 1-month period, determined by scores on the expanded BPRS (Overall &amp; Gorham, 1962) of 3 or less on the items hallucinations, conceptual disorganization, suspiciousness and unusual thought content.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1) Unable to converse in, or read English without an interpreter; (2)Severe intellectual disability; (3)Persistent positive psychotic symptoms; and (4) Psychotic disorder due to a medical condition.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The randomisation procedure was set up in a Microsoft Access database and the sequence of randomisation was concealed until the interventions were assigned per case. Randomisation was controlled and concealed by the statistician involved in the study and was not available to any other members of the team.</concealment>
    <sequence>Random number computer program, password secured</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>An effectiveness study with treatment as usual as a control</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>29/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eli Lily</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Lily-Map Consortium</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ORYGEN Youth Health and Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Belinda Newman</name>
      <address>ORYGEN Youth Health
35 Poplar Rd
Parkville VIC 3052</address>
      <phone>+61 412848864</phone>
      <fax />
      <email>belinda.newman@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>John Gleeson</name>
      <address>ORYGEN Youth Health
35 Poplar Rd
Parkville VIC 3052</address>
      <phone>+61 409386523</phone>
      <fax />
      <email>jgleeson@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>